Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

DR. LAL PATHLABS LTD.

NSE : LALPATHLABBSE : 539524ISIN CODE : INE600L01024Industry : Hospital & Healthcare ServicesHouse : Arvind Lal

BSE1329.309.35 (+0.71 %)

PREV CLOSE ( ) 1319.95

OPEN PRICE ( ) 1322.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 8588

TODAY'S LOW / HIGH ( )1285.00 1339.35

52 WK LOW / HIGH ( )1202.72 1771.3

NSE1328.705.1 (+0.39 %)

PREV CLOSE( ) 1323.60

OPEN PRICE ( ) 1319.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 1328.70 (74)

VOLUME 167885

TODAY'S LOW / HIGH( ) 1285.00 1358.00

52 WK LOW / HIGH ( )1175.78 1770

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 14-02 1995

Management Info

Arvind Lal - Chairman - Managing Director

Registered Office

Address Block E,Sector 18,Rohini,
New Delhi,
Delhi-110085

Phone 011-30258600

Email lalpathlabs@lalpathlabs.com

Website www.lalpathlabs.com

Registrars Details

MUFG Intime India Pvt Ltd.

Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi

Listing : BSE, NSE

NEWS

30Jan Allotment of Equity shares under ESOP
Inter alia, approved:- 1. Declaration of 3rd Interim Dividend of INR 3...

06Jan Dr. Lal PathLabs sets new standard in
Dr. Lal PathLabs has launched its new-age Diagnostic Experience Centre -..

06Jan Dr. Lal PathLabs informs about press r
Pursuant to Regulation 30 of the Listing Regulations, Dr. Lal PathLabs h..

22Dec Dr. Lal PathLabs informs about allotme
In further to its earlier intimation(s) dated December 8, 2025 & Dec..

26Nov Lal PathLabs informs about press release
Pursuant to Regulation 30 of the Listing Regulations, Lal PathLabs has i..

Financials

Rs. in Millions

	QTR Dec 25	ANNUAL 25
Net Profit	921	4973
Gross Profit	1231	6213
Operating Profit	2003	7770
Net Sales	6321	23516

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Kovai Medical Center (BSE) 5097.95 (0.82%)	M.Cap ( in Cr)5578.31
Kaya (BSE) 269.45 (8.65%)	M.Cap ( in Cr)409.23
Vijaya Diagnostic (BSE) 895.85 (1.40%)	M.Cap ( in Cr)8662.38
Apollo Hospital Ent. (BSE) 7316.35 (0.16%)	M.Cap ( in Cr)105197.89
Global Health (BSE) 1001.05 (1.11%)	M.Cap ( in Cr)26907.26

Shareholding Pattern

	PROMOTERS	53.21%
	MUTUAL FUNDS/UTI	16.84%
	NON-INSTITUTION	7.43%
	FI/BANKS/INSURANCE	2.18%
	GOVERNMENT	0.01%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
NJ ELSS Tax Saver S...	3.99
Bajaj Finserv Healt...	2.82
PGIM India Healthca...	2.36
Nippon India Pharma...	2.31
Quantum Ethical Fun...	2.15
DSP Nifty Smallcap2...	2.09
NJ Flexi Cap Fund-Reg(G)	2.03

Risk Disclosures on Derivatives

Smart Quotes

DR. LAL PATHLABS LTD.